Mineralys Therapeutics (MLYS) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ocular Therapeutix (OCUL) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 54.5% versus a loss of 67.4%. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | OCUL |
|---|---|---|
| Share price | $13.66 | $5.57 |
| Market cap | $1.21B | $1.23B |
| 1-day change | -3.53% | -4.95% |
| YTD return | -62.36% | -54.12% |
| 1-year return | -67.38% | -54.49% |
| 5-year return | — | -14.83% |
| EPS (TTM) | $-4.30 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $51.95M |
| Revenue growth (YoY) | — | -18.47% |
| Net income (latest FY) | $-154.65M | $-265.94M |
| Gross margin | — | 87.35% |
| Operating margin | — | -519.75% |
| Net margin | — | -511.90% |
| 52-week high | $44.13 | $16.44 |
| 52-week low | $13.57 | $5.54 |
| Distance from 52-week high | -69.05% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.89% | +361.94% |
| Average volume | 1.55M | 3.03M |
| Shares outstanding | 88.56M | 220.02M |
| Employees | 76 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OCUL has outperformed MLYS by 12.9 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
MLYS vs OCUL FAQ
Which is bigger, Mineralys Therapeutics or Ocular Therapeutix?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.21B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or OCUL?
OCUL returned -54.49% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.